已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer

前列腺癌 基因复制 疾病 生物 合成致死 雄激素受体 杀伤力 医学 肿瘤科 转录组 前列腺 生物信息学 内科学 癌症研究 基因组不稳定性 癌症 色丛 表型 精密医学 基因组学 生存分析 损失函数 PI3K/AKT/mTOR通路 总体生存率 雄激素 遗传学 乳腺癌 基因表达谱 计算生物学 基因组
作者
Ryan James Rebernick,Liat Hammer,Mahnoor Naseer Gondal,Abhijit Parolia,Yi‐Mi Wu,Noshad Hosseini,Matthew J. Schipper,Anbarasu Kumaraswamy,Matthew McFarlane,Xuhong Cao,Phillip Lee Palmbos,Megan E.V. Caram,David Carl Smith,Sarah Elizabeth Yentz,MI-OncoSeq Team,Stand-Up To Cancer Team,Maha H. Hussain,Thomas Christopher Westbrook,Daniel Eidelberg Spratt,William C. Jackson
出处
期刊: [Cold Spring Harbor Laboratory]
标识
DOI:10.64898/2026.06.18.733209
摘要

SUMMARY Despite extensive characterization, the molecular determinants that shape disease progression and therapeutic outcomes in metastatic castration-resistant prostate cancer (mCRPC) remain incompletely defined. This large, multi-institutional analysis reveals that the genomic determinants of outcomes in primary prostate cancer are distinct from those in castration-resistant disease. We identify androgen-regulated MYC fusions as potent primary genetic drivers catalyzing early progression. Additionally, across independent mCRPC cohorts, we validate TP53, RB1 , and CDKN1B alterations as the strongest genetic drivers of poor survival. Mechanistically, CDKN1B loss induces an AR-positive epithelial–mesenchymal transition rather than neuroendocrine differentiation, while TP53 loss triggers whole-genome duplication and subsequent adaptive copy-number gains. Within TP53-altered tumors, AR amplifications confer improved survival while AR mutations are protective regardless of TP53 status. Integrating these genomic events with transcriptomic phenotypes, we derive CAPrisk, a multi-omic prognostic classifier. CAPrisk stratifies patients with mCRPC into three risk groups with >33-month survival differences and predicts outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. Together, these findings expand the clinical utility of genomic profiling in advanced prostate cancer and establish a framework for risk stratification in lethal disease. IN BRIEF (eTOC BLURB) Rebernick et al. analyze a multi-institutional cohort of 1,331 prostate cancer samples and identify the genomic determinants of progression to lethal, castration-resistant disease. They define rare AR-regulated MYC fusions and haploinsufficient CDKN1B loss as drivers of poor outcome while highlighting AR alterations as predictors of improved prognosis. They develop CAPrisk, a multi-omic classifier that stratifies patient outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. HIGHLIGHTS – AR-regulated MYC fusions are rare (∼2%) truncal events driving aggressive disease. – Distinct AR alterations drive favorable outcomes in TP53 -altered and non-altered contexts. – Haploinsufficient CDKN1B loss predicts poor survival in AR-positive tumors. – A multi-omic model predicts outcomes across four standard-of-care therapies. MI-OncoSeq Team Chandan Kumar, Erica Rabban, Kayla Muschong, Lakshmi P. Kunju, Javed Siddiqui, Yu Ning, Rui Wang, Fengyun Su, Yelena Kleyman-Smith, Josh N. Vo, Jin Chen, Rahul Mannan Stand Up To Cancer Team Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Matteo Benelli, Eliezer M. Van Allen, Andrea Sboner, Tarcisio Fedrizzi, Juan Miguel Mosquera, Brian D. Robinson, Navonil De Sarkar, Lakshmi P. Kunju, Scott Tomlins, Daniel Nava Rodrigues, Massimo Loda, Anuradha Gopalan, Victor E. Reuter, Colin C. Pritchard, Joaquin Mateo, Diletta Bianchini, Susana Miranda, Suzanne Carreira, Pasquale Rescigno, Julie Filipenko, Jacob Vinson, Robert B. Montgomery, Himisha Beltran, Elisabeth I. Heath, Howard I. Scher, Philip W. Kantoff, Mary-Ellen Taplin, Nikolaus Schultz, Johann S. deBono, Francesca Demichelis, Peter S. Nelson, Mark A. Rubin, Charles Sawyers

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liuliu_发布了新的文献求助10
刚刚
penicillin完成签到 ,获得积分10
刚刚
刚刚
可爱的函函的应助被lllin采纳,获得10
刚刚
Oo完成签到 ,获得积分10
2秒前
万能图书馆的应助被AN1AN采纳,获得10
2秒前
2秒前
脑洞疼的应助被DearWhite采纳,获得10
3秒前
3秒前
4秒前
4秒前
阿南发布了新的文献求助10
5秒前
南淮完成签到,获得积分10
6秒前
6秒前
zyj发布了新的文献求助10
7秒前
8秒前
华仔的应助被友好大树采纳,获得10
8秒前
10秒前
mofudyc完成签到,获得积分10
11秒前
fufu发布了新的文献求助10
11秒前
谢谢好心人研途顺完成签到,获得积分10
11秒前
认真问柳发布了新的文献求助10
12秒前
Lucas的应助被xc采纳,获得10
12秒前
ReynaLi完成签到 ,获得积分10
12秒前
遥章发布了新的文献求助10
13秒前
丘比特的应助被SaSS采纳,获得10
14秒前
15秒前
16秒前
16秒前
鲤鱼初柳完成签到 ,获得积分10
16秒前
17秒前
17秒前
GPTea的应助被高冷汉堡包采纳,获得20
19秒前
19秒前
20秒前
111发布了新的文献求助10
20秒前
ljz发布了新的文献求助10
20秒前
zfj完成签到 ,获得积分10
21秒前
聪明海云完成签到,获得积分20
22秒前
机灵猕猴桃完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189694
求助须知:如何正确求助?哪些是违规求助? 9576952
关于积分的说明 21850481
捐赠科研通 7787646
什么是DOI,文献DOI怎么找? 3435759
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482624